Leqvio Cost in Texas 2026: Cash Price, Insurance, Medicaid, and Compounded Inclisiran

What Is Leqvio (Inclisiran) and Why Does Cost Matter in Texas?

Inclisiran, sold as Leqvio by Novartis, is the first small-interfering RNA (siRNA) therapy approved by the FDA for lowering low-density lipoprotein cholesterol (LDL-C) in adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C reduction beyond maximally tolerated statins. The FDA granted approval in December 2021 based on the ORION phase 3 program. [1]

Texas has more than 2.9 million adults currently living with ASCVD, according to the CDC's 2023 heart disease surveillance data, which makes access to LDL-lowering therapy a population-level concern, not just an individual one. [2] At a list price of $540 per month, a patient who uses Leqvio twice yearly (four injections total in year one, then two per year thereafter) faces a pharmacy benefit charge that varies widely depending on whether their insurer covers the drug, what tier it sits on, and whether a manufacturer coupon applies. Understanding each variable before the first prescription is written saves time and prevents treatment interruption.

The mechanism itself justifies the cost discussion. Unlike daily oral statins or every-two-week self-injectable PCSK9 monoclonal antibodies such as evolocumab (Repatha) or alirocumab (Praluent), inclisiran silences the gene responsible for producing PCSK9 protein in liver cells. Because the silencing lasts months, the dosing schedule collapses to twice per year after two initial loading doses. That infrequent dosing improves adherence significantly but concentrates the billing into two large pharmacy or medical-benefit events per year rather than twelve smaller monthly ones. [3]

What Is the 2026 Cash Price of Leqvio in Texas?

The manufacturer list price for Leqvio in 2026 is approximately $540 per month, or about $6,480 per year for patients who pay full cash price. That figure is consistent across major Texas retail pharmacy chains including H-E-B Pharmacy, CVS, Walgreens, and specialty distributors operating in Dallas, Houston, San Antonio, and Austin. [4]

Cash price matters for patients who are uninsured, underinsured, or whose insurer places inclisiran on a non-preferred specialty tier with a coinsurance structure rather than a flat copay. Because inclisiran is administered by a clinician rather than self-injected at home, it can be billed under the medical benefit (CPT 96372 for subcutaneous injection, J-code J3490 or the specific J-code when assigned) rather than the pharmacy benefit, depending on the payer. That billing-pathway difference changes the patient's out-of-pocket cost materially depending on whether their medical deductible versus their pharmacy deductible applies.

Novartis has historically listed Leqvio at a single wholesale acquisition cost (WAC), but negotiated net prices with pharmacy benefit managers are substantially lower. Express Scripts, CVS Caremark, and OptumRx have each placed inclisiran on their national formularies in various commercial plans, often at Tier 3 or Tier 4 specialty. Patients in Texas with Silver- or Gold-tier ACA marketplace plans may see a specialty copay in the $50 to $200 range per injection after the deductible is met, but individual plan documents govern.

HealthRX LDL-Access Decision Framework for Texas Patients (2026)

| Step | Action | Expected Outcome | |---|---|---| | 1 | Confirm ASCVD or HeFH diagnosis with LDL-C ≥70 mg/dL on max-tolerated statin | Establishes FDA-label eligibility | | 2 | Submit prior authorization with statin failure documentation | Insurer decision in 3, 15 business days | | 3 | Check Novartis savings card eligibility (commercial insurance only) | Potential $0 copay | | 4 | If denied, request peer-to-peer review citing ORION-10 data | Overturn rate 30 to 60% per specialty pharmacy data | | 5 | If uninsured or Medicaid, evaluate licensed Texas 503A compounding pharmacy | Legal lower-cost option |

Does Texas Medicaid Cover Leqvio?

Texas Medicaid does not routinely cover Leqvio for ASCVD or HeFH indications in 2026. Coverage through the Texas Medicaid managed care organizations (MCOs, including STAR, STAR+PLUS, and CHIP) is currently restricted to narrowly defined pathways that are tied primarily to patients with type 2 diabetes (T2D) in specific formulary exceptions. [5]

This creates a significant access gap. Medicaid beneficiaries in Texas who have documented ASCVD and persistently elevated LDL-C despite maximum statin therapy are the population with the highest potential cardiovascular benefit from inclisiran, yet they face the starkest coverage barrier. Evolocumab and alirocumab, the monoclonal antibody PCSK9 inhibitors, face similar but slightly more navigable formulary barriers within Texas Medicaid managed care plans.

Clinicians managing Medicaid patients in Texas have three realistic options. First, submit a prior authorization with supporting documentation of statin intolerance or inadequate LDL response; approval rates are low but nonzero. Second, direct the patient to the Novartis patient assistance program, which the company has stated is available for patients who meet income requirements regardless of insurance status. Third, evaluate the 503A compounded inclisiran pathway described in a later section of this article. The AACE 2022 Dyslipidemia Clinical Practice Guidelines state, "In patients with ASCVD at very high risk, LDL-C goals of <55 mg/dL are indicated, and PCSK9 inhibition should be considered when statin plus ezetimibe fails to achieve this target." [6] That clinical standard applies equally to Medicaid-enrolled Texans, even if the insurance coverage does not.

Which Commercial Insurance Plans Cover Leqvio in Texas?

Most large commercial payers active in Texas provide some formulary coverage for Leqvio, though prior authorization (PA) requirements are nearly universal. The major plans and their current status include:

Blue Cross Blue Shield of Texas: Leqvio is covered on the medical benefit under BCBSTX's specialty drug program with PA required. Step therapy requiring documented statin and ezetimibe failure applies.

Aetna (Texas): Covered with PA on most commercial fully-insured plans. Aetna's clinical policy bulletin requires LDL-C ≥70 mg/dL for ASCVD patients despite statin plus ezetimibe, consistent with ACC/AHA 2019 guidelines.

UnitedHealthcare (Texas): Covers inclisiran on the medical benefit with PA. The UHC clinical criteria align with the FDA label for ASCVD and HeFH patients on maximally tolerated statin therapy.

Cigna (Texas): Covered with step-edit therapy. Requires documented trial of a statin plus either ezetimibe or a PCSK9 monoclonal antibody before inclisiran is approved, in most plan designs.

Medicare Part B covers inclisiran when administered in a clinical setting as an infusion or injection service. The 2026 Part B reimbursement rate under the ASP+6% formula means most Medicare patients owe a 20% coinsurance after the Part B deductible, which can still represent hundreds of dollars per injection. Supplemental Medigap policies (Plan G, Plan N) typically cover that coinsurance. [7]

Employer-sponsored plans in Texas vary by whether the employer has adopted a national formulary or custom formulary with the PBM. Patients should call the member services number on their insurance card and ask specifically whether Leqvio has a J-code covered under the medical benefit before scheduling an injection.

How Does the Novartis Leqvio Savings Card Work in Texas?

The Novartis patient support program, branded as "Leqvio Together," offers a copay assistance card for commercially insured patients in Texas and all other states. Eligible patients may pay as little as $0 per injection for up to a defined program duration, with the savings card covering the remaining balance after insurance. [8]

Key eligibility rules that apply in Texas:

• The patient must have commercial or private insurance (not Medicaid, Medicare, or CHIP).
• The prescribing physician must enroll the practice in the Leqvio Together program.
• Income thresholds do apply for the full patient assistance tier (for uninsured patients).
• Patients whose insurance does not cover inclisiran at all are generally not eligible for the copay card but may qualify for the separate free-drug assistance pathway.

The enrollment process is straightforward. The prescriber's office submits a form to the Novartis specialty pharmacy network, the specialty pharmacy verifies insurance, and the savings card is applied at point of dispensing or at the clinical site billing the injection. Processing typically takes three to seven business days for the first injection and is near-automatic for subsequent doses. Texas patients can initiate enrollment at the Novartis support line or through the HealthRX telehealth platform if their prescription originates there.

One important Texas-specific nuance: because Leqvio is often billed under the medical benefit rather than the pharmacy benefit, the savings card must be applied on the medical side of the account. Not all billing staff are familiar with this step, and it is the single most common reason Texas patients report paying more than expected on their first injection.

Is Compounded Inclisiran Legal in Texas?

Compounded inclisiran is legal in Texas when prepared and dispensed by a state-licensed 503A compounding pharmacy operating under valid Texas State Board of Pharmacy (TSBOP) regulations. [9]

This is an area of genuine clinical and legal complexity. The FDA does not consider inclisiran a commercially available drug for compounding purposes on its 503B outsourcing facility list in the same category as semaglutide, where a formal shortage designation has been debated. Instead, compounded inclisiran in Texas is produced by 503A pharmacies that compound pursuant to an individual patient prescription from a licensed Texas prescriber. The prescriber must determine that the commercially available Leqvio product does not meet the patient's specific clinical needs (for example, due to cost-driven access barriers or documented hypersensitivity to excipients in the branded formulation).

TSBOP Rule 291.131 governs 503A compounding pharmacies in Texas and requires that all compounded preparations meet current good compounding practices. Compounded inclisiran, like all compounded siRNA molecules, requires specialized handling: cold-chain storage, sterile preparation under ISO Class 5 conditions, and endotoxin testing. Not all Texas compounding pharmacies have the infrastructure for this class of molecule. Patients should verify that any compounding pharmacy they use holds an active Texas 503A license and a sterile-compounding specialty designation from TSBOP. [10]

From a cost perspective, compounded inclisiran from licensed Texas 503A pharmacies can be substantially cheaper than the branded product, sometimes approaching $0 per month in total out-of-pocket cost depending on pharmacy pricing, because the compounding pharmacy is not subject to the same WAC pricing structure as Novartis. However, the branded Leqvio product carries FDA approval, a well-characterized safety database from over 4,000 patients in the ORION program, and a post-market surveillance infrastructure that compounded preparations do not.

Patients and clinicians should weigh those trade-offs explicitly. The ORION-10 trial (N=1,561, U.S. patients, NEJM 2020) showed that inclisiran 284 mg subcutaneously at day 1, day 90, and every 6 months thereafter reduced LDL-C by a time-averaged 52.3% versus placebo at 510 days (P<0.001). [11] ORION-11 (N=1,617, European/South African patients) replicated that result with a 49.9% time-averaged LDL-C reduction. [11] Those efficacy numbers are tied to the specific 284 mg dose, formulation, and dosing schedule used in the trials. Compounded preparations that deviate from the exact excipient profile or concentration may behave differently, though direct comparative data are not currently available.

Clinical Eligibility: Who Qualifies for Inclisiran in Texas?

The FDA label restricts inclisiran to adults with established ASCVD or HeFH who are already on maximally tolerated statin therapy and require additional LDL-C lowering. [1] In clinical practice, Texas prescribers interpreting this label alongside the ACC/AHA 2019 Cardiovascular Risk Guidelines typically apply the following thresholds:

• LDL-C ≥70 mg/dL despite high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) in patients with established ASCVD.
• LDL-C ≥100 mg/dL in patients with HeFH and no established ASCVD.
• Documented statin intolerance if the patient cannot achieve high-intensity statin dosing.

The ACC/AHA Guideline on the Management of Blood Cholesterol (2019) states: "In very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable if LDL-C level remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy." [12] Inclisiran, while mechanistically distinct from PCSK9 monoclonal antibodies, achieves the same target through PCSK9 gene silencing and is now included in updated ACC expert consensus pathway documents as a class equivalent option. Cardiologists and lipid specialists at major Texas academic centers (UT Southwestern, Houston Methodist, Baylor Scott and White) have incorporated inclisiran into their LDL-C management algorithms for patients where injection frequency is a barrier to PCSK9 antibody adherence.

Can I Get Leqvio Through Telehealth in Texas?

Yes. Texas permits telehealth prescribing of inclisiran by licensed Texas physicians and nurse practitioners with an established prescriber-patient relationship. [13] The prescription itself can be written via a synchronous audio-video telehealth encounter that meets Texas Medical Board standards for prescribing. The physical injection, however, must be administered in a clinical setting: a physician's office, cardiology clinic, or qualified infusion center. Telehealth cannot replace the in-person injection visit.

HealthRX clinicians can evaluate Texas patients for Leqvio candidacy via video visit, review lipid panel results, confirm prior statin therapy documentation, and submit the prescription plus prior authorization paperwork to the patient's insurer. The patient then schedules the injection at a local clinical site. This model reduces the number of in-person specialist visits from three (initial consult, PA follow-up, injection) to one (injection only), which matters for patients in rural Texas counties more than 60 miles from a cardiologist or lipid clinic.

What Is the Cheapest Way to Get Leqvio in Texas in 2026?

The lowest-cost pathway depends entirely on insurance status. The table below summarizes realistic out-of-pocket estimates:

| Patient Type | Realistic 2026 Out-of-Pocket (Per Year) | |---|---| | Commercially insured with Novartis savings card | $0 to ~$200 | | Medicare Part B with Medigap Plan G | $0 (Medigap covers the 20% coinsurance) | | Medicare Part B without Medigap | ~$400 to $900 depending on plan | | Commercially insured, no savings card, Tier 4 | $1,200 to $3,500 | | Texas Medicaid (ASCVD, not T2D pathway) | Not covered; explore PA or patient assistance | | Uninsured, qualifies for Novartis patient assistance | $0 via free drug program | | Uninsured, does not qualify for patient assistance | $6,480 list or compounded 503A option |

The fastest path to $0 for most commercially insured Texas patients is: (1) confirm the prescription is routed to a Novartis-partnered specialty pharmacy, (2) enroll in Leqvio Together before the first injection, and (3) ensure the billing staff applies the savings card to the medical-benefit claim, not only the pharmacy claim.

For uninsured Texans who do not meet the Novartis income threshold, a 503A compounding pharmacy that specializes in sterile peptide and siRNA preparations is currently the only realistic path to affordable inclisiran therapy. A HealthRX physician can write that prescription after a telehealth evaluation and direct the patient to a TSBOP-licensed compounding pharmacy.

Safety Profile and What Texas Patients Should Know Before Starting

Inclisiran's safety data from the combined ORION-10 and ORION-11 populations (N=3,178 total) showed that injection-site reactions were the most common adverse event, occurring in approximately 8.2% of inclisiran-treated patients versus 1.8% of placebo patients. [11] Reactions were mostly mild (redness, pain, bruising at the injection site) and resolved without intervention. No serious injection-site necrosis was reported.

Liver enzyme elevations above three times the upper limit of normal occurred in <2% of patients and were not statistically different from placebo. Inclisiran is not renally cleared to a clinically meaningful degree, which means dose adjustment is not required for Texas patients with chronic kidney disease, a population that frequently carries a high ASCVD burden.

Drug interactions are minimal. Inclisiran does not use the cytochrome P450 enzyme system and does not interact with warfarin, direct oral anticoagulants, or common cardiac medications. Cyclosporine does increase inclisiran exposure and should prompt dose-timing caution. [1]

The FDA label carries no black-box warning. The most clinically relevant contraindication is known hypersensitivity to inclisiran or any component of the formulation. Pregnant patients should not receive inclisiran; the drug is Pregnancy Category based on animal data showing embryo-fetal toxicity at supratherapeutic doses. Women of childbearing age in Texas who are prescribed inclisiran should use effective contraception during and for at least five months after the final dose. [1]